Cancer Patients Who Elect to Die at Home Live Longer
By HospiMedica International staff writers Posted on 12 Apr 2016 |
Terminal cancer patients who choose to die at home live longer than those who choose to die at a hospital, according to a new study.
Researchers at the University of Tsukuba (Japan), Tohoku University (Japan), and other institutions across Japan conducted a multicenter, prospective cohort study from September 2012 through April 2014 in 58 specialist palliative care services to explore the potential differences in the survival time of cancer patients dying at home or in a hospital. In all, the study recruited 2,426 patients, of which 2,069 patients were analyzed; 1,582 receiving hospital-based palliative care and 487 receiving home-based palliative care.
The results revealed that eventually, 1,607 patients actually died in a hospital, and 462 patients died at home, with the survival time of patients who died at home significantly longer than the survival time of patients who died in a hospital. The median survival time was 13 days compared to 9 days in the daily prognosis group, and 36 days versus 29 days in the weekly prognosis group. No significant difference was found in the months' prognosis group. The study was published on March 28, 2016, in Cancer.
“Patients and their families tend to worry that home care won’t provide the quality of care that a hospital will. However, spending the last days or months at home doesn’t necessarily mean life would be shortened,” said lead author Jun Hamano, MD, an assistant professor of internal medicine at the University of Tsukuba. “Patients, families, and clinicians should be reassured that good home hospice care does not shorten patient life, and even may achieve longer survival.”
Most patients with advanced cancer would prefer to die at home, and many people in the United States, United Kingdom, and other countries are realizing this wish. But in other countries, such as Japan, Germany, Greece, and Portugal a trend towards institutionalized dying persists. But despite trends, the most frequent location of death for those dying from cancer is still a hospital, with marked variations in the odds of home death depending on illness-related, individual, and environmental factors.
Related Links:
University of Tsukuba
Tohoku University
Researchers at the University of Tsukuba (Japan), Tohoku University (Japan), and other institutions across Japan conducted a multicenter, prospective cohort study from September 2012 through April 2014 in 58 specialist palliative care services to explore the potential differences in the survival time of cancer patients dying at home or in a hospital. In all, the study recruited 2,426 patients, of which 2,069 patients were analyzed; 1,582 receiving hospital-based palliative care and 487 receiving home-based palliative care.
The results revealed that eventually, 1,607 patients actually died in a hospital, and 462 patients died at home, with the survival time of patients who died at home significantly longer than the survival time of patients who died in a hospital. The median survival time was 13 days compared to 9 days in the daily prognosis group, and 36 days versus 29 days in the weekly prognosis group. No significant difference was found in the months' prognosis group. The study was published on March 28, 2016, in Cancer.
“Patients and their families tend to worry that home care won’t provide the quality of care that a hospital will. However, spending the last days or months at home doesn’t necessarily mean life would be shortened,” said lead author Jun Hamano, MD, an assistant professor of internal medicine at the University of Tsukuba. “Patients, families, and clinicians should be reassured that good home hospice care does not shorten patient life, and even may achieve longer survival.”
Most patients with advanced cancer would prefer to die at home, and many people in the United States, United Kingdom, and other countries are realizing this wish. But in other countries, such as Japan, Germany, Greece, and Portugal a trend towards institutionalized dying persists. But despite trends, the most frequent location of death for those dying from cancer is still a hospital, with marked variations in the odds of home death depending on illness-related, individual, and environmental factors.
Related Links:
University of Tsukuba
Tohoku University
Latest Critical Care News
- Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension
- New Understanding of Barrett’s Esophagus Formation to Enable Earlier Intervention and Diagnosis
- 3D Printed Functional Human Islets Could Transform Type 1 Diabetes Treatment
- AI Model Predicts ICU mortality in Heart Failure Patients
- Smart Capsule Offers Real-Time Profiling Across GI Tract
- Ultra-Thin Implant Helps Patients with Spinal Cord Injury Recover Lost Functions
- Portable Cell Therapy Device to Enable Rapid On-Demand Modification of RBCs at POC
- Monitoring Airborne Fungal Spores Could Help Predict COVID-19 & Flu Surges
- New System Measures Blood Sodium Without Needles
- Sleep Data from Wearable Device May Help Predict Preterm Birth
- AI Tool Interprets Echocardiograms in Minutes
- Electrochemical Catheter Hub Prevents Bloodstream Infections
- Noninvasive Double Microbubble Delivery Approach Marks Breakthrough in Brain Cancer Treatment
- Self-Healing Skin-Like Material to Find Applications in Health Monitoring, Surgery and Implants
- Highly-Sensitive Electronic Skin Allows Robots to Feel Heat, Pain and Pressure
- AI-Powered Wearable Sensor Predicts Labor Onset in Pregnant Women
Channels
Surgical Techniques
view channel
Neuroform Atlas Stent-Assisted Coiling Found Effective Even in Smaller Arteries
Aneurysms, especially when located in the brain, can be life-threatening if not treated effectively. Intracranial aneurysms, caused by the dilation of blood vessels due to weaknesses in the vessel wall,... Read more
New Surgical Technique Safely Removes Giant Nerve Tumors
Giant plexiform neurofibromas (PNF) are benign tumors commonly associated with neurofibromatosis Type 1 (NF1), a genetic disorder affecting approximately 1 in 3,000 live births. These tumors, which occur... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more